header logo image


Page 1,070«..1020..1,0691,0701,0711,072..1,0801,090..»

Stubborn blindness | Frontline – Frontline

February 18th, 2017 12:42 pm

Jaitleys attempt to underplay the damage caused by demonetisation contrasts with the somewhat more sober assessment of the Economic Survey prepared by his Ministry.

THE Union Budget is only one of several instruments of economic policy available to the government. It must necessarily take into account not just the national context and the prevailing distribution of economic and political power among the various social classes in the country, but also the international context, more than ever before, given that the sum of Indias exports and imports amounts to a substantial share of the countrys gross domestic product (GDP). This years Budget, which was presented a few months after the shock and awe of demonetisation, had to contend with that move as well. Notwithstanding these constraints and taking into account the fact that the media hype over the Budget is possibly a bit over the top, the Union Budget is nonetheless very important as the total expenditure of the Union government accounts for between one-eighths and one-sevenths of the countrys GDP.

The Union Budget for 2017-18 was presented in Parliament on the first day of February instead of the last day of that month, as had been the practice for many years. The other distinctive feature this year was that the Railway Budget was subsumed within the Union Budget and not presented separately. Both these features have some negative implications. The database for the Budget is weakened somewhat by its advancement. The subsuming of the Railway Budget within the Union Budget weakens the special attention that the Railways, with its truly all-India character, deserves. Some read this subsuming as a prelude to the privatisation of the Railways.

Be these as they may, Arun Jaitleys fourth Budget as Union Finance Minister is wilfully blind to the serious negative economic impact of the demonetisation exercise imposed on the country by the Central government.

In a Budget speech that was true to form in terms of being long on rhetoric and short on substance, Jaitley hailed demonetisation as a momentous initiative and claimed that it would produce great benefits in the long run. The Minister presented little evidence to back his claim. His attempt to underplay the damage caused by demonetisation contrasts with the somewhat more sober, even if still wishful, assessment of the Economic Survey prepared by his Ministry.

The fact of the matter is that the demonetisation measure inflicted on an economy that was already showing some evidence of decline in momentum has caused considerable economic harm already, not to mention the tragic and entirely avoidable loss of more than a hundred lives. Estimates by various sources, including the Centre for Monitoring the Indian Economy (CMIE) and the All India Manufacturers Organisation (AIMO) and several independent economists, suggest substantial monetary loss and a decline of between 1 and 2 percentage points in the rate of economic growth.

Economists of widely different persuasions have shown a rare unanimity in highlighting the serious negative impact of the measure on aggregate demand in the economy. Given the damage caused by demonetisation and the consequent decline in aggregate demand, there was a general expectation that the Union Budget would provide a substantial stimulus to the economy to counteract the deflationary impact of demonetisation. However, an examination of the tax and expenditure proposals, which constitute the core of any budget, shows a failure to recognise the need for a substantial stimulus to the economy.

The Budget Estimate (B.E.) of total expenditure for 2017-18 is Rs.21.47 lakh crore as against a Revised Estimate (R.E.) for 2016-17 of Rs.20.14 lakh crore. This works out to a less-than-7 per cent increase in nominal terms. Taking inflation into account and viewed against a GDP growth estimated at 6.5-6.75 per cent, this is no stimulus at all. The total budgeted expenditure of the Union government for 2017-18 is 12.7 per cent of the GDP as against 13.4 per cent in 2016-17, a reduction in relative terms.

There is a great deal of rhetoric in the Budget speech on large increases in allocations for agriculture and farmers welfare, rural development, education and health. There is also the claim of significantly enlarged spending on infrastructure. The Budget speech suggests a thrust towards agriculture and allied activities and rural development. But the allocation for these two sectors taken together rises from Rs.167,768 crore in R.E. 2016-17 to Rs.187,223 crore in B.E. 2017-18, an increase of 11.5 per cent in nominal terms, implying only a modest increase in real terms. The allocation for education and health was Rs.114,806 crore in R.E. 2016-17. It has risen to Rs.130,215 crore in B.E. 2017-18, again a rather modest increase given the countrys overall low spending on these key sectors. The total expenditure on infrastructure as a share of Budget outlay is also marginally lower in B.E. 2017-18 compared with R.E. 2016-17.

An especially important negative impact of demonetisation has been on employment in the informal sector. There was widespread expectation that the Budget would address this issue by substantially increasing allocation for the rural employment guarantee scheme and possibly initiating a similar urban employment guarantee scheme. However, the allocation for the Mahatma Gandhi National Rural Employment Guarantee Scheme (MGNREGS) in B.E. 2017-18, at Rs.48,000 crore, is barely more than the R.E. 2016-17 figure of Rs.47,499 crore. Given the increase in wages for MGNREGS work, there will be a decline in the number of days of employment per household registered in the scheme. A larger point also needs to be made. As data from the Labour Bureau surveys remind us, job creation has nosedived over the past year, and this was a key issue for the Budget to take into account. However, it has made no serious effort in that direction.

Turning to receipts, the tax proposals in the Budget are estimated to result in a loss of Rs.20,000 crore in direct tax revenues. This continues the trend under the present government of persistent tax giveaways in respect of direct taxes even while the rhetoric is about widening the tax base and increasing the share of direct taxes. What is happening is that the indirect tax burden, a large share of which is borne by ordinary working people, is rising steadily. For instance, the revised excise duty collection in 2015-16 was Rs.2.88 lakh crore as against a B.E. of Rs.2.29 lakh crore. In 2016-17, the excise duty collection was Rs.3.87 lakh crore as against a B.E. of Rs.3.19 lakh crore.

Over the last three years, we have seen the abolition of wealth tax in a country characterised by obscene wealth inequality. We have also seen repeated overtures to tax evaders even while the rhetoric around demonetisation was on wiping out black money. These steps do not enhance the credibility of the governments morality plays. In respect of corporate income taxes, there is reasonable ground for eliminating numerous exemptions. The clamour for lower tax rates on corporate profits is to be assessed against the reality of effective tax rates of hardly 25 per cent on profits accruing to large corporate entities. The several lakh crores in revenue foregone on account of concessions to robust corporate and individual entities does not speak of equity in budget-making.

The economic philosophy underlying the Budget is one which sees the state as, at best, a necessary evil, and believes that the sole path to rapid growth and social well-being is through incentivising corporate investment. It also places exclusive emphasis on so-called fiscal prudence, which is interpreted to mean minimising fiscal deficits essentially through expenditure reduction. The self-serving argument that a lowering of tax rates will lead to an improvement in compliance is not sustained by evidence from across the world. The reason is simple enough: if the marginal costs of tax evasion are perceived to be lower than the benefits from such evasion, compliance need not improve at all.

Excerpt from:
Stubborn blindness | Frontline - Frontline

Read More...

Hello, again, Dolly – The Economist

February 18th, 2017 12:41 pm

Xn`Dr(6bE3s8zfPF$=$;a{w|3%o !m~>ZxN&zUV2mMUt#rk75nLMmukVqnpC3B|l;#kjB|lFCQ|O3+ob9;]Kkt7+} Zx9GhBNz)Q;% m=Y# rwHj[p1_QVDCDbhA]kS^W_E]-0_.L,ka=4wlNa#.r=`GZ7&?zZO}O #:ZOzQ{4: i>|Ua/pN Zhh_$,maG>k!@V@F44LzO^5 LDAVqQq.!R_@Ol

+mYZQe,nFppP=1 u=uB~:= F'Iwv}%qJ a$xIOHr4gguI |xP_U7'G+q#pp"rL~:0]X~8gNDs/kO8T:U(4Xvo1%RDIc+xGY.gY>$">s0TK<8K@.H_Uzx HTwV-VNgNt)9~S< V3+= g3qiB;}q'mjk!yq*c~lLz?S-S@6vxbyT(@i joTAhk$f:D1Kfg+PhqhFc'#`YeU`bN.ywyi%u]8'QJ7t{M XafnC&Pu6gQX%'88V rh4uc?[dV=,-f'Y^dZF6zcN:-)8cy*DLz' 0kNdxpZLK4gEDYu49 NW4pXt-VdVZ%)2)C,snm)|[`pr 6k1/wg4lWM^B~&5Gj;Gj'+:rhYQavfS1Dz!_#jFW-*KYlQW8UQ ^;8E7Hz3%anh!t[3ujhqvh^z9Hki`h,aE>v)H;AL`J,8%Ycx!S~C^q5K"n]>K_Rh<;f8b9w5$ 9'kcY6C;@BI?f+-]/Emi>M% TWSEHBA`#X&n{_Q U44Sjep7#Qmj%r@r*$a9+bqB*3 _R9TMz12hAIz$;`Dr$7(DW`[PF`=Z,3{S ztVHKo 2sJ/#-Bx{ c:Oo5}>'8K 5 XV5`$ ]_yImJ=X?Az!L p fjE2ukU/BOc`1F~{S@Mn*%'J*@i{B PnKRX} Vp+v'6P8kt-/|CW,5!:N[gwerCm@o6sof4tiKllfGM :QEdr>+PBxncu|Hy;790j[6 YQqEL86n S`)Ux5]}ZEm,4{h27:kQ}WUq>t{YlKJ}qC GtG?!9-],wO`$eglA-4;>s )cSR_r_,%3OYS&4esxg/-Vd/cCjJv|D&rS6%rbH7Jq?uDp] {U uc]PnWnd8*#a7o]QY%#q.(z3HG{Fqk3(vF {W9(c>#}pTy: hW*X*4j6K.[JFe(x'Jo!gr"m8Mxs-M0FJ VH,8|YtYLm!$S*G8Yo;S=J;li`3&B^*I:1N14ONQ[6-NE=siTqOr [c Q !OCeBCAgG!%.q,z 7Tu/]tf:jS4qZM8c6!8DK4>q +A=6IU?33{,el%s!N2A19RF4ffE0I-``P/]=k0+<=A49)Cp>K0:@hs6ceP]%%VWpYHmGjvc`5nzFH:b$9Wkm|i#]4Xfgt?X_<<>p"p!=DBD) AN,4HOB = d*L)R_2qQe&ZD*5x@<[V){EbWT49?=x :t '@Qh@-=iEBP6rOSL KO>3~sY@BQu2R@CF>Jkt3dFoJoI?,L`MjY:)D SAz;sR5|H2m$H;HF/m}#ANPg[ep.e`5.~mBb

_}w1Zi:1kC;fG|cy SIKw(w{5_7j_8h_WPBt}tz} 6igh/*1TM=gjka[-3 }Yya9u>=NL5&t;b71m+xx=vpyy?P[a.&aF<)__mnOL[TB[kOW!v:r7M[kq_4qH1FSzY_1)Y&sy6yFRgy{; $7#&KTL]H/|(}Z"s,{Rl.n}xcf&9*9D{q{DN]]W0HqAB/{YHsZfW/7~W[f2q6nD/_w6/$iFnt9'riXF"Mrpc9&[ecI>#:G_N, v= y-N< Y)dw,e&YqM~tQ"cn/;.>6Y'BXHQ1.H#XmlB^RLM3Clw`#R[+8H"8,y +|l`${ EfXdTlFtsB{4,Z`cp4Mb'+fp @*ND)Sm??cT8R#2wV1k<>3 9xy qI DxW.K-~-%VtG&05XNz+W 5>'"T =1+f?pbB3*;0 5Z g 'jrnob }@wDk{#PN,3N$>4DFG;6*LUe]bBd2UNU UC3[6p%nY#@Q]D5:`dQ`'uc"7Nnifc=DZSHaE@yu mA%1R;CuIXt$V"[a}1./PU9(s!,vX$/(Aa%YLFOP pc6S{MHKx|9@,7e3H7:M7K^N!9Er6DjqjS7^T.Bz~,)qJ/:z?NSX:Qu@ akFL(,'$B{_!hN;qx )T8jvX,x?|0M(*I+AER`,lP#g(cP"$A@7tkTf`"G(Tq2j C' rNs}4Rs%` 7KH2X'P*AaC-Gx&6P`/,29-k00rFOtfzDbLQ^(F:NzG!BMS>0 hL`Rv#;m#HS_// Efg_DH9UK18^da(/tu:dh}H@n[M=_Ag 3X]HMKS EP&3c5LrLXT0i=Qz{`yfY iHHZ9< @qJi m'|`~)uWQ/~9?w:7JJ"#U];?/M"-7w')o=@VC4k#%mC-}}1(;I!.eF3KuJPfs8qn^uk1[7f5z(?m\Ch:?GykWU.=V~cyo7eq?%}R2}"]RzYjo+enQk`y&LfiB|! {^jh7j>uQ=^x; >% TlfcmX'5Bx|`!4j5AQV#4a($`*iQ/%][$s4.wV]"Ic[!8wk2_;H5]i9yGYjI5Lfu ^/z. oxLAMBPu=X"t]]C!{Kd{E*<)U?MoqG~N4W75=N,_|~H+>_>"Sj[CuIIa$;wW2>M- 'pQFZQKEl9Ut qX?H3Su `= (qY b{st$9EK$cnL1J7-YjM>{bT-5i+R0NfoZv ,Iv$h&jn"Ar2 `|B$.bPR94GfEO(oJQt%R&6NRZ@W^*h)m"HgJg)A&Q8hCo8n1`lZyS|'hTcV]]2~btE&4OGK.kC; $,l`Es!nM,I51P ek"[v+^4l.c5Z9ZP P!{?MnX H]un|{[lo 1z?,Qs 2C}k9|5D<>]FUw:5=*i?s/tq1]3@}~h^YPdc4!|KNRKGqQuN|;As8:LQVW9Kjc+EC]~F'/YLn5S_F[# ^xAw;gY0,H ~A0MJwur(Ky.NH0)t] 7)-Bv=]./8I?.79%T:}fReuAV41#ddxMeGT&K{I! % 0!r5"SUSdPFTUI]QhtO6P}IK*BFw!t`*~(xZ1+&Xj9u yQrzWA`j]2b9J6^!AQ-g vqq",'w;^fE&5am2z1?&c|wMgrhILxGvLPt':O,wj -cOSfo/el^"&T?TZ|qC rR?7RRZ A-pe/?i7M{thaiOTRli+:^q9I9/Rf.w.f|9(R`u!C}@InDQsco*{+g| n6_E/@CH]7|OWMc`|O>X_^x K> {|wP? }#<1l)..a9+=w}FCBt^opmz]rFS6PeS}apqBtj[mO/^j/]>{r-iCJ=sj!mo34_u,[YMECMgmpIkFUmA8?CuT'S %;JJYk]+!V^=p"QopVh~ky5e)QGJ<('yDT}faNaZvH1Yit~5-VkC@he3V7>9^r:Hm{) 4ica41 =w$;JaP:o2KFhxTSf}ZIA xqj7rFX.,ju1Lk7PsJ$RO979tJCnE^x*Mzy<-[L Mct' &gDNvoL8qqQ-T=]N?o:^x|M'SR[ (8F2 b`7&:ry$9;V6p}XMIE~( %^$2E](C8S WX{IXb9M t&xTVi;Qz0iu(MF0Z@iahFF'atF'atF &@i(SS}J @MCZ)n,o$ig>u% E=+D[`hPz Mmh&9[aT'iHm@hSw -P M&BcD0&Nha8g,R` 0:1 [`FX+0: MmhmBhuB'L(@<&4M`a &(m 1KsSetfCtdWPmtDik6PB$vEz;BBt@Z}`K 060:H71jlSQ7w>O-J$5 {/#=T]N{w*5bp?r*Oy 0_!V,l[%w>8f|y3 o'm`dw- d &WAt0}^4<#GcFu888|P(q(ZEd'9)#GYC,|rI1+Tpo8 5"%> v < "D`1j/iG?N$w>=D:j*wXAz)cUBaf'/h72p7 U~~J{~8-on~k+^O+MWd]4 cSHn0#2Dn~dciodDth,ZB+mt`(Sr0{0j(K"w +<)^A$UENqK- tQ)C3]Q (0KEm`H""G_QP0B2:9tXA)+5 N0 %d%ww]E7Qf;:IP ^>M>Cs_ }t*2,p{-w_L5a0jTh1W]qC {gB_cu mR%KcwFvrCqBCe|t EWc}}OLa3AtnC2v51Pq_o_pH*s%5M=bKqLq_^qzH~iv1'/n KgS5Xe JLa*w Ni.l}(9wbN[u<[H!(KC[)|D^C 1;A=bsO#^ lbCHXHW90j865FBSY(BnQuu6;"E7RI 0wHzlDDc ^SOPm4RD:?>;p&X^&cl4PnN6 y8 wN/ovD(SF3Ge-p&d;T#&yTaGuI|(s)%piy$xOJ@KHv;>iFdf*.nhb*wvCO"ddhwU;vddY"QKnUqGyX?SW. Hh v@zs#CqVvj[_ nOW#7vc!_z!A$72Wc"pWX^25wvnr='inJVwV6[ul5nX#-bO!X W hD (=bVzwtT6WVHrVEGvw{xE| X&Y .LSaKbpzs7"Nh+%_5=~I.AI>fWj[4MsG|g+]K8 /@E'Rm_@"jN?FfEUMI$L$T;Iiz8:,%oYn7]?G1' t|W?::jaB ~ +Wa^WntR"#(7A%Uo?x"M?8?D2Ko$2094$HqGC}rMle^*M U8v(%GE c_K)` SxEP)Rde+dbBF?xV_ -jI9,aH_0R_X:FbIxI3U!!L lJ7BU3eZcJi!e}$^r0/$q-M@T.|7+*]rRlB~()!dJ'U!!&eI!G8dc UddECz-0r/Jr.TJJ~t?2Ew, K,i{ ?>3GX`lZ}9c=EcYQ!|cOE1Jb:TT{W-]^4*j_x!_`wpUP/3CAH9r7Ua]6X7(CLjvv|? XY&Ll93j[)F?XqW#u}#yY-4y@l(v?=~fa~2y2>w0 >gPRPa.y$ALmPU%08R8&(SdidOKJn-]IE3H:SiKU.mp0rNWwm`K>?))vu^lw9DamaXF*xAj]K!j+r2VTT3U,) (l,erW46}xtB#NLq`d ;mBvya?1c"R5Cr )iqS+"%Oo9SFYPGuK8nC$Kq+1'tY3tW#yYaXT?%~c{;pOM28"lI Gwyd7P4lMc!j@8<&NcLerXn5Adn]=PL.8:X/SZ[t:R##jZOHX->?lyD}?9B$ ue

View post:
Hello, again, Dolly - The Economist

Read More...

Puma Biotechnology Inc (PBYI) Soars 7.76% on February 17 … – Equities.com

February 18th, 2017 12:41 pm

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a good day on the market for Friday February 17 as shares jumped 7.76% to close at $40.25. About 1.37 million shares traded hands on 9,969 trades for the day, compared with an average daily volume of 928,303 shares out of a total float of 36.82 million. After opening the trading day at $37.25, shares of Puma Biotechnology Inc stayed within a range of $40.50 to $36.70.

With today's gains, Puma Biotechnology Inc now has a market cap of $1.48 billion. Shares of Puma Biotechnology Inc have been trading within a range of $73.27 and $19.74 over the last year, and it had a 50-day SMA of $34.47 and a 200-day SMA of $41.58.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 156 employees. Its CEO is Alan H. Auerbach.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Continued here:
Puma Biotechnology Inc (PBYI) Soars 7.76% on February 17 ... - Equities.com

Read More...

iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB),Health … – ETF Daily News (blog)

February 18th, 2017 12:41 pm

February 17, 2017 6:33am NASDAQ:IBB NYSE:XLV

From Taki Tsaklanos: Biotechnology was once the darling of stock market investors. Not so anymore, since the summer of 2015 the sector collapsed from 400 points to 250 points in the IBB ETF.

Likewise, the health stock market sector lost its status of outperformer as the XLV ETF went from 75 points to 62 points. Note that biotech is part of the health sector (XLV).

Biotechnology is now showing the first signs of life. The IBB ETF is up 3 percent on the week.

We warned readers to watch closely the 250 level in this alert: Biotechnology and Health Sector Testing Long Time Support. Later on, we noticed that biotech refused to break down, and started to show a pattern of higher lows. Right now, the biotech stock market sector is testing a breakout level. Things will really get bullish once 300 points in the IBB ETF is cleared.

The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) fell $1.78 (-0.61%) in premarket trading Friday. Year-to-date, IBB has gained 10.40%, versus a 5.01% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

The broader healthcare sector (XLV ETF) looks even more interesting. It recovered its losses, and is now ready to test all-time highs. Make no mistake, 75 points is a very important price level. A triple-test is significant as, mostly, three tests are sufficient for a breakout. However, a failure to breakout, after 3 tests, is bearish to say the least.

The Health Care SPDR ETF (NYSE:XLV) was unchanged in premarket trading Friday. Year-to-date, XLV has gained 6.70%, versus a 5.01% rise in the benchmark S&P 500 index during the same period.

XLV currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #1 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Investing Haven.

Tags: biotech Health Care NASDAQ:IBB NYSE:XLV

Categories: NASDAQ:IBB NYSE:XLV

The rest is here:
iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB),Health ... - ETF Daily News (blog)

Read More...

Diet to cure your arthritis: THIS everyday food could be making symptoms WORSE – Express.co.uk

February 18th, 2017 12:41 pm

Experts have said inflammation could be addressed by what people eat, adding that every day foods including sugar and saturated fat can dramatically affect the conditions.

One of the everyday foods people could benefit from cutting out, they suggest, is vegetable oil - found in many processed foods - as too much Omega 6 in the diet can trigger inflammation.

Chronic low grade inflammation is linked to all the common diseases out there, said Philip Calder, Professor of Nutritional Immunology at Southampton University.

Understandably this is why there has been such a huge focus in the last decade on understanding it and trying to find ways to reduce it.

Think of inflammation as essentially a sign something is wrong and the body is try to find a way to resolve it.

GETTY

For example, a thumb will become swollen, heat up and painful if you hit it with a hammer this inflammation response warns your body something is amiss and then can kick start the healing process.

But significantly it is short-lived. What is different is when we experience intermittent or recurrent inflammation.

Where it is not turned off it becomes chronic, says Professor Calder.

Chronic inflammation - that persists and serves no purpose damages the body and is a key factor in causing illness and is now recognised as the underlying basis of a significant number of diseases.

GETTY

Chronic low grade inflammation is linked to all the common diseases out there

Professor Philip Calder

Professor Calder added: Many of the factors of a modern Western lifestyle - like taking little or no exercise and a diet often high in sugar and bad fats appear to make it easier for the body to become inflamed.

He said there is no magical food group which can reduce inflammation but components of some foods may be able to regulate or dampen down the inflammatory response.

These components can be found in a typical Mediterranean diet, one that has been shown to lower cholesterol and reduce symptoms of inflammatory conditions like rheumatoid arthritis.

Rob Hobson Head of Nutrition at Healthspan said people should be eating oily fish - rich in omega 3, fibrous pulses, berries, nuts, dark green and other brightly coloured vegetables, which contain antioxidants and other polyphenols to help quell inflammation in the body.

Processed foods rich in refined carbohydrates - including sugar - and saturated fats can exacerbate the inflammatory process, he said.

Getty

1 of 10

Foods to avoid if you are suffering with Gout

Both experts said having too much omega 6 in the diet - found in vegetable oils like sunflower and safflower and found in many processed foods.

These fats oxidise easily, depleting the body of antioxidants and potentially causing inflammation and mutation in cells.

Switch to extra virgin olive oil and avoid margarine and too much meat, said Rob.

There is also increasing evidence that overeating leads to an inflammatory response in the body.

If you measure the blood of an obese person you will find higher levels of inflammatory chemicals than in someone who is not overweight, said Professor Calder.

GETTY

And heres the interesting thing: lose weight and those levels of inflammatory cells return to normal.

Experts also state there are herbs and spices which can help people reduce inflammation, including ginger and tumeric.

The active components of the ginger root known as gingerols are potent antioxidants and exhibit anti-inflammatory effects that have been proven to help reduce migraines and period pain.

People who dont get much turmeric or ginger in their diet can consider taking a supplement like Healthspans OptiTurmeric, 15.95 or Ginger Extract, 13.95.

The rest is here:
Diet to cure your arthritis: THIS everyday food could be making symptoms WORSE - Express.co.uk

Read More...

Nine months of rheumatoid arthritis suppression with one stem cell dose? – MedCity News

February 18th, 2017 12:41 pm

Dividing mesenchymal stem cells

Its the kind of the data the field has worked towards for years.

Rheumatoid arthritis (RA) patients given a single intravenous dose ofMesoblastsnovel stem cell therapy were still demonstrating therapeutic benefits nine months later, according to new Phase 2 data from the Melbourne, Australia-based company.

While much larger Phase 3 studies are needed to validate the results, the data offer a tantalizing look at what optimized and targeted regenerative medicines could do as the field moves closer to an approval.

The study involved 48 patients that were resistant to frontline TNF-alpha therapies, such as Enbrel, Remicade, and Humira.

While these drugs have revolutionized the field and generated billions in revenue around20-40 percent of patients treated with a TNF inhibitor dont achieve a significant reduction in symptoms. Theyre non-responders. Others become resistant over time or experience adverse events.

When TNF inhibitors are off the table, patients are typically prescribed second-line drugs such as Rituxan. These, however, are not as effective and come with a range of serious side effects.

CEOSilviu Itescu said Mesoblasts mesenchymal precursor cells (MPCs) have demonstrated virtually no toxicity. The immune system doesnt register them as foreign so theres no negative immune response.The cells also appear targeted, intrinsically moving towards sites of inflammation and embedding themselves in the tissue.

The way the cells work is, they have receptors on their surface that are activated by every major cytokine that is important in progressive rheumatoid arthritis, including TNF, IL-1, IL-6, IL-17, Itescu explained. Those cytokines drive the disease and also bind to receptors on our cells. And when they bind to our cells they activate the cells to release other factors that switch off the very cells that made those cytokines.

In other words, MPCs interfere with the feed forward production of inflammatory molecules. Because the cells are addressing multiple pathways, he believes the therapy has an edge on the biologics inhibiting TNF-alpha or others key targets. It is also getting to the heart of the inflammation and disease, not simply knocking the immune system back.

Listed on both the NASDAQ and the Australian Stock Exchange (ASX), Mesoblast is evaluating its platform to a wide range of diseases. For each indication, the cells are delineated and optimized. Mesoblasts portfolio, Itescu said, is the most advanced in the stem cell field.

At the front of the pack is MSC-100-IV, a Phase 3 therapy for pediatric graft-versus-host disease (GvHD). MSC-100-IV secured orphan drug designation in the U.S., paving the way for an accelerated approval. The company is expecting a data readout in the third-quarter of this year.

Two other product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development for advanced chronic heart failure and chronic low back pain due to degenerative disc disease.

In late December, U.S.-based MallinckrodtPharmaceuticals took an option on the GvHD and lower back pain programs.

When it comes to manufacturing, Itescu said the cells are designed to scale. The foundation for the supply chain is the allogeneic nature of the cells they can be administered to any patient.

Its not a problem for us, its an advantage, Itsecu said about the production logistics.Weve been at this for ten years and weve focused the entire thing on a scalable manufacturing platform using a unique subtype that can be used off-the-shelf and that can be industrially manufactured.

There are plenty of potential customers if the therapy is approved.

Rheumatoid arthritis is particularly lucrative. As Global Business Intelligencenotes, in 2013, three TNF-a-targeting biologics Humira, Remicade, and Enbrel were ranked among the top-10 best-selling drugs in the world, with global revenues of $11.1 billion, $9.9 billion, and $8.9 billion respectively.

Photo: Mesoblast

View post:
Nine months of rheumatoid arthritis suppression with one stem cell dose? - MedCity News

Read More...

Baricitinib Better for Rheumatoid Arthritis than Humira – National Pain Report

February 18th, 2017 12:41 pm

By Staff

The New England Journal of Medicine published supplementary data, which show that people with moderate-to-severe rheumatoid arthritis (RA) who took the oral Janus kinase inhibitor baricitinib had better outcomes through 52 weeks compared to adalimumab (Humira).

This is an exciting time for rheumatology, with potential new treatments for rheumatoid arthritis on the horizon. The RA-BEAM study of baricitinib is the first phase 3 trial showing that a once-daily, oral treatment significantly improved clinical outcomes compared with a current standard of care, injectable adalimumab used with background methotrexate therapy, said Peter Taylor, M.A., Ph.D., F.R.C.P., study author and Norman Collisson chair of Musculoskeletal Sciences in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford.

In the RA-BEAM study, researchers studies more than 1,300 people who did not have an adequate response to methotrexate, but continued the use of methotrexate throughout the duration of the study. Participants were randomized to placebo once daily (n=488), baricitinib 4 mg once daily (n=487) or adalimumab 40 mg biweekly (n=330). At the 24th week, participants taking placebo crossed over to the baricitinib treatment group. The design of the head-to-head study and statistical analysis plan included prespecified and controlled for multiple testing for both non-inferiority and superiority of baricitinib compared with adalimumab.

A higher proportion of participants taking baricitinib achieved ACR50 and ACR70 response composite scores that represent at least 50 percent and 70 percent improvement, respectively, in multiple components of RA disease activity compared to adalimumab. This was observed as early as week 8 and continued through week 52.

These improvements were statistically significant compared to adalimumab at weeks 12, 20, 28, 32 and 40. At week 52, both ACR50 and ACR70 rates were higher in the baricitinib group compared to adalimumab, although only ACR50 was statistically significant.

Serious adverse events were observed in 8% for baricitinib and 4% for Adalimumab. Major adverse cardiovascular events (MACE) were reported in less than 1% of patients in both the baricitinib and adalimumab groups (baseline through 52 weeks). A total of 5 deaths were reported in the study (1 placebo, 2 baricitinib, 1 adalimumab and 1 placebo rescued to baricitinib).

These data demonstrate that baricitinib could provide another treatment option for people with rheumatoid arthritis, Taylor added.

Read the original here:
Baricitinib Better for Rheumatoid Arthritis than Humira - National Pain Report

Read More...

6 Things You Need to Know About Switching Psoriatic Arthritis Treatments – Everyday Health (blog)

February 18th, 2017 12:41 pm

Finding the right treatment to keep your psoriatic arthritis under control can take time. The first, second, or even third may not work for managing your particular condition.

Treatment change would come about in two different situations for psoriatic arthritis, says Reshma Marri-Gottam, MD, a rheumatologist at St. John Providence health system in Detroit. One would be theyre not tolerating the medication or they have an adverse effect or reaction to the medication, or the risk outweighs the benefits. The other is theyre just not responding to the medication.

It may be that your body has built up a resistance to one drug or that the disease itself is ramping up, especially if youve only been managing the symptoms rather than the source of the symptoms.

Usually we are adjusting medications due to active joint inflammation and active skin disease, explains Kelly Weselman, MD, a rheumatologist at Wellstar Rheumatology in Atlanta and chair of the American College of Rheumatology communications and marketing committee. Sometimes we change a medication because it is not effective at all, she says. Sometimes the medication shows partial benefit, but the patient and I might decide we can do better with an alternative medication strategy.

The right treatment plan can make all the difference in controlling your symptoms and allowing you to continue your daily activities.

Although this is not a curable disease, it can often be put into remission, Dr. Weselman says. There are certainly patients who we just cannot get into complete remission, but usually we can find a treatment regimen that improves their quality of life.

Here are the questions you should ask to determine whether its time to change treatment and what to expect.

Every drug comes with side effects and risks, and these can be the reason some patients want to stop taking a drug. The most important thing is to be open with your doctor about what you can and cannot handle.

Be honest with your physician about ongoing symptoms that are bothersome. Your appointment is the best time to discuss changes, so arrive prepared, Weselman says. Recognize that every treatment carries some degree of risk, and lack of appropriate treatment also carries risk. Many decisions must be made in person, either due to a need for the doctor to examine a particular area or to have effective discussions about the available options.

I explain to patients our ladder of treatment options as well as the risks, benefits, and potency of each agent, Weselman says. We discuss costs as well.The options are finite, so we need to discuss all options to avoid running out of treatments.

The first drug most people use to treat psoriatic arthritis is a nonsteroidal anti-inflammatory drug (NSAID). These over-the-counter drugs, such as ibuprofen(Advil, Motrin) or naproxen(Aleve), treat the pain and inflammation but not the underlying cause of the disease.

The next step up from NSAIDs are disease-modifying anti-rheumatic drugs (DMARDs). These drugs, such as methotrexate, do not actually modify psoriatic arthritis disease but can prevent its progression.

Biologics, which are made from living organisms, work by targeting specific proteins or cells in the immune system.

Patients may receive a temporary course of corticosteroids during any of their treatment plans to stop a particularly bad flare-up.

We discuss guidelines in treatment and standards of care and how that applies to their specific situation, Weselman says. Spending a few minutes giving the patient information helps us to make decisions together.

Its only human to want instant relief, but some drugs take time to really kick in. Weselman and Dr. Marri-Gottam recommend allowing three months for a new medication to begin working.

It can be frustrating for patients waiting to see if a medication is effective, but if we give up on a treatment too quickly, we risk losing potentially effective treatments, Weselman says.

The most current framework for thinking about psoriatic arthritis treatment today is that combination therapy is better than monotherapy, Marri-Gottam says. That means that using two drugs simultaneously can often achieve better results than just one.

Usually methotrexate is combined with a biologic agent, Weselman says.Sometimes sulfasalazine is a part of the combination.

Sometimes doctors have to try one treatment before another simply to make sure you dont end up paying out of pocket.

We tend to use the medications that have been out on the market the longest, and we try to do what we think is right for the patient. But sometimes the insurance company dictates what we can and cant use, Marri-Gottam says.

One company might require a patient to try adalimumab(Humira) before etancercept(Embrel), for example; while another company may require a different protocol. Insurance companies often require patients try a DMARD before moving on to biologics.

Methotrexate is the first med I usually start with, even if theyre a good candidate for a biologic, Marri-Gottam says. With DMARDs, if theres any dose changes that can happen, you try to give a fair chance to that medication before you say, Hey, this isnt going to work anymore.

Some drugs restrict the activities you can engage in or delay goals you may want to achieve, such as starting a family. Its important to discuss with your doctor what youre willing to do and give up.

Younger patients should definitely think about whether they want to have kids, Marri-Gottam says. I advise patients that they need to be on birth control if taking methotrexate because it is known to be harmful to the fetus.

Not enough data exists about biologics to know if they can cause harm, so its currently recommended not to take biologics while pregnant or trying to conceive either.

Alcohol is another big one for methotrexate, Marri-Gottam says. If youre on methotrexate, you shouldnt drink at all. Methotrexate is heavy on the liver, so if youre taking that and drinking alcohol, which is processed by the liver, its too much for the liver to handle for some patients.

Go here to read the rest:
6 Things You Need to Know About Switching Psoriatic Arthritis Treatments - Everyday Health (blog)

Read More...

Gene Therapy for Rheumatoid Arthritis gets Approval to Start … – Labiotech.eu (blog)

February 18th, 2017 12:41 pm

Arthrogen will start a Phase Ib trial for a gene therapy aiming to treat rheumatoid arthritis with a single injection and reduce costs for patients.

Arthrogen,based in Amsterdam, is developing local gene therapies for inflammatory diseases. The biotech company has now announced it has received approval to start a Phase Ib trial with its lead candidate, ART-I02, in patients with rheumatoid arthritis who still suffer from inflamed joints despitemultiple treatments.

The clinical trial will be conducted by the Centre for Human Drug Research (CHDR) in Leiden, with collaboration from other University Medical Centers in the Netherlands. Patients will start to be recruited in the first quarter of this year and results are expected by the end of 2018.

ART-I02 consists of a recombinant adeno-associatedviral vector (rAAV) genetically engineered to encode the human interferon (hIFN-) protein, which has anti-inflammatory activity.By including an inflammation-inducible promoter in the genetic construct, the gene is only expressed when the patient suffers flares of acute pain and inflammation.

Founded in 2005 as a joint venture between the Dubai Bone & Joint Center (DBAJ) in the United Arab Emirates and the Academic Medical Center (AMC) in Amsterdam, Arthrogen has managed to raise almost 15M so far to support its pipeline for inflammatory disease.

One of the advantages of ART-I02 is that its delivered locallyin the rheumatic joint, only affecting the target area to minimize side effects. In addition, gene therapy offers a long-lasting treatment with a single injection, which can significantly reduce costs for patients in the long term. However, Arthrogen will have to be careful to not follow the steps of its neighboruniQure, whose firstcommercial gene therapy was a failure because of pricing issues.

Rheumatoid arthritis is a big market, expected to generate 32.5B ($34.6B) by 2020. The space is crowded, but by then blockbusters like top-seller Humira will no longer be protected by patents in both the US and Europe, leading the way for biosimilars and other options affordable in the long term such as gene therapy.

Images byMidas Anim; Tefi /Shutterstock

Original post:
Gene Therapy for Rheumatoid Arthritis gets Approval to Start ... - Labiotech.eu (blog)

Read More...

Stem Cell Professionals: Stem Cell Therapy in York, Pa

February 18th, 2017 12:41 pm

Knee Pain

Knee pain, often caused by sport injuries, is incredibly common. If your knee pain is getting worse learn how you can stay out of surgery with Stem Cell Therapy.

The hip joint is the largest joint in the human body but this joint isn't indestructible. Over time and overuse joint pain can occur. Click to learn how you can be treated with Stem Cell Therapy.

Shoulder pain is typically a result from previous injury to the shoulder joint or tendons. Click to see how Stems Cell Therapy can help.

Plantar Fasciitis is one of the most common types of heel pain. The pain you experience during plantar fasciitis is actually inflammation in a ligament in your foot. This inflammation is commonly treated with stem cell therapy.

The lower back is a problematic area for many older adults. This part of the body is a very complex and interconnected network of muscles, discs, nerves and bones that can cause a number of problems that range from arthritis to muscle spasms.

Elbow joints are much less prone to wear and tear as other joints but pain is typically a result from years of repetitive motion. Click to see how we can help with Stem Cell Therapy.

Wrist pain is a common complaint. It's typically caused by sudden impacts and repetitive stress. Check out how Stem Cell therapy can alleviate your pain.

Like other joints injury and overuse are the typical causes of ankle pain. However, gout and joint space are among other causes. Click to see how you can benefit from Stem Cells.

Your neck or cervical spine is another problem area for many people. Like the lower back the neck is made up of discs, bones, muscles and ligaments which can cause people to experience many painful symptoms.

Read the rest here:
Stem Cell Professionals: Stem Cell Therapy in York, Pa

Read More...

Stem Cell Therapy – Premier Regenerative Stem Cell

February 18th, 2017 12:41 pm

The Re-Brand Premier Regenerative Stem Cell and Wellness Centers, recently rebranded their business from Premier Stem Cell Institute, in response to expanding locations, technology, and treatments. This move reflects the growth and success this company has undergone recently and goals for the future.

PRSC and Wellness Centers President, Kandace Stolz said, This rebrand is the culmination of the years of work weve put into stem cell medicine. Were growing and healing more patients than we ever have before, this new name reflects those accomplishments and gives us room grow. We are so thrilled for this move and cant wait to do even more for our patients going forward.

Premier Regenerative Stem Cell and Wellness Centers will continue to partner with the NFL Alumni Association and treat current and former professional athletes. PRSC remains dedicated to studying stem cell treatment by collecting and tracking data to further stem cell progress and maximize results for all patients. PRSCs commitment to being a leader in stem cell and regenerative medicine is unwavering and will continue to innovate and learn to heal and improve the quality of life for all patients.

About Premier Regenerative Stem Cell and Wellness Centers: PRSC is a leading research and treatment facility in Colorado, providing innovative medicine and therapies for those in pain by harnessing the bodys own natural healing power of stem cells. As team of cutting-edge medical experts, PRSC is dedicated to treating patients by using their own stem cells to heal, improve quality of life, and battle the acute pain of chronic illnesses. Premier Regenerative Stem Cell and Wellness Center locations include Loveland Colorado, Dallas Texas, St. Louis, Missouri, and Jacksonville, Florida. PRSC has plans to expand to other major cities across the United States in the near future.

See the original post here:
Stem Cell Therapy - Premier Regenerative Stem Cell

Read More...

Stem cell therapy adds pep to pets – Columbus Telegram

February 18th, 2017 12:41 pm

COLUMBUS For the past year, Dr. Todd Paczosa has been practicing what he calls the future of medicine.

The veterinarian treats his four-legged patients through stem cell therapy.

Im not anti-antibiotic, anti-medicine. I just believe that even in the future of cancer treatment that it is going to come down to your body healing itself, Paczosa said.

The process involves removing fatty tissue from a patient, extracting stem cells, then injecting the cells back into the animal's joints to promote healing.

Paczosa said he researched the treatment for about a decade before deciding to offer it at Redstone Veterinary Hospital in Columbus.

Our body is full of cells that heal. You get cut, your body heals. What we are doing is taking those cells, waking them up and saying, Hey, lets go to work, he said.

Since he started offering stem cell therapy last March, 17 dogs, horses and cattle have used the treatment. One of those patients is Butch, a 9-year-old schnauzer owned by Marge Biester of Columbus that was suffering from a strained ligament and achy joints.

He was really hurting. I had to do something for him, Biester said, adding that Butch wasnt putting much weight on his back leg when he walked.

The treatment was done in January. Butch was put under anesthesia to retrieve the fat tissue. Using equipment in-house, the stem cells were extracted and injected back into the dog that same day.

Paczosa, who has been a veterinarian for 23 years, said the entire process can be done in a day.

Biester noticed results in about two weeks.Butch wasnt doing his three-legged walk anymore and began acting like a more-active, younger version of himself.

Im amazed at how quickly he recovered, she said.

Paczosa said all of the animals he has treated so far have shown improvement.

One of these days, we will have one that doesnt work. Thats just medicine, but we havent had one yet, he said.

The possibility of the stem cell therapy not working can be a turnoff for some pet owners who might find it difficult to spend $1,900 to $2,400 for the treatment at Redstone. If it does work, Paczosa said the therapy is less expensive in the long run than putting an animal on medication for extended periods of time to ease the pain from arthritis.

Other pluses, he said, are that the regenerative therapy isnt as invasive as surgery and anti-rejection drugs don't have to be used since the cells come from the same animal.More than one joint can also be treated at a time and it can eliminate the use of non-steroidal anti-inflammatory drugs.

The biggest risks are putting the animal under anesthesia and infection of the surgical site where the fatty tissue is removed, typically from the shoulder area or abdomen.

Stem cell therapy is practiced at a few hundred veterinary clinics in the country. Redstone works with the animal stem cell company MediVet Biologics and uses that companys in-house technology.

Paczosa said owners have come from other states to use the therapy at his Columbus clinic.

Initial results from the procedure lasts about two years. An option to bank stem cells from a pet is available. A portion of what is taken can be stored in a lab and used again in the future.

For Paczosa's patients, results have been quick and ongoing.

Most owners have seen a dramatic improvement in two weeks. Our first patient is still seeing improvements, he said.

Read more here:
Stem cell therapy adds pep to pets - Columbus Telegram

Read More...

Sparta family raises diabetes awareness – The Sparta Independent

February 17th, 2017 5:48 am

Published Feb 15, 2017 at 11:08 am (Updated Feb 15, 2017)

Chris Gildea, with sons Austin and Henry, volunteering at an American Diabetes Association event. Photo provided by Katie Gildea.

'); //-->

By Meghan Byers

SPARTA For the Gildea family, diabetes isn't just a disease; it's a daily battle. Sparta residents Katie and Chris Gildea, along with their two young sons, ages 3 and 7, will volunteer this June at the American Diabetes Association's upcoming Skylands Tour de Cure, an event which helps fund diabetes research. Chris Gildea, who has type 1 diabetes, has volunteered with the ADA for 10 years. This year, the Gildea family plans to help out at each Tour de Cure event in New Jersey.

"It's a 24-hours-a-day, seven-days-a-week job, living with diabetes," said Katie Gildea. "Diabetes robs you of your ability to lead a care-free life."

The Tour de Cure is the ADA's biggest fundraiser. The Skylands event, which will be held at Waterloo Village, will include both a cycling portion and "fun run & walk" for non-cyclists.

While raising money for a cure is a top priority, Katie Gildea believes that education is equally important, especially when it comes to confronting the social stigma often associated with diabetes.

"A lot of people don't realize that Type 1 diabetes is separate from Type 2 diabetes, and that anyone can have it. A lot of people think it's a choice," she said. "People always tell my husband, 'You look so healthy.' But diabetes doesn't look a certain way. It can affect anyone of any age, any lifestyle."

Chris Gildea, who works at Becton-Dickinson, a company that provides diabetes care products, enjoys an athletic lifestyle despite his disease. "My kids think he's a superhero," said Katie Gildea. "He always tells them never give up, never surrender, and that's how we are with this never give up, never surrender."

According to the ADA, 1.4 million Americans are diagnosed with diabetes each year, and approximately 1.25 million Americans have type 1 diabetes. In 2010, diabetes was the seventh leading cause of death in the United States.

"When you have something like this that can affect your children," said Katie Gildea, "you'll do anything in your power to rid the world of it."

The Skylands Tour de Cure will take place June 4 at Waterloo Village in Stanhope, with a kickoff event taking place on March 23 at Czig Meister Brewery in Hackettstown.

More information and event registration is available at http://www.diabetes.org/skylands, and anyone interested in volunteering can email Katie Gildea at katiehug@hotmail.com.

Here is the original post:
Sparta family raises diabetes awareness - The Sparta Independent

Read More...

ColorVisionTesting | Colorblind

February 17th, 2017 5:45 am

This on-line color vision test consists of four cards from the popular color vision test "Color Vision Testing Made Easy". Try and find a circle, star, and/or a square on the Demonstration Card, Card # 1, and Card #2. Try and find a dog, boat, balloon or car on Card # 3. You only have 3 seconds to give the correct answer on each card.

Try to find a circle, star, and/or square on the Demonstration Card

Card # 1 - Try and find a circle, star, and/or square in 3 seconds.

Card # 2 - Try and find a circle, star, and/or square in 3 seconds.

Try and find a dog, boat, balloon, or car (as shown in the below demonstration card) on Card # 3.

Important Disclaimer: Due to the fact there are so many different monitor screens displaying different colors, the accuracy of this "on-line" version of "Color Vision Testing Made Easy" is limited. This webpage is for "screening" purposes only, not a "diagnosis". For a diagnosis, you should see your vision care professional and be given the complete test using all 14 plates of "Color Vision Testing Made Easy" under controlled testing conditions and the proper lighting. You can order the book "Color Vision Testing Made Easy" by clicking on the below picture. Please let the distributor know you were referred by Dr. Waggoner.

Click here if you want to continue testing for colorblindness by taking another popular color vision test like this one called the Pseudoisochromatic Plate Ishihara Compatible (PIPIC) Color Vision Test 24 Plate Edition. It uses numbers instead of objects.

Go here to see the original:
ColorVisionTesting | Colorblind

Read More...

Blindness: UITH examines 2500 children in kwara – BusinessDay … – BusinessDay

February 17th, 2017 5:45 am

Dupe Ademola Popoo la, anOphthalmologist with the University of Ilorin Teaching Hospital (UITH) said as parts of efforts to prevent and curtail blindness among children in Kwara State, 2500 children have been examined.

Popoola made this known on Wednesday in Ilorin, during a visit of Kwara first lady and medical personnel to the Children Hospital at Centre Igboro in Ilorin.

According to her, the state government has enacted law that makes visionscreening compulsory for children from zero to five years. Adding that because of the effort of the state government, a foundation; the USAID has shown interest in the project where they donated some equipment worth thousands of dollars.

Popoola said: 2500 children had so far been examined and some referral has been made to General Hospital in the state. However, four children were diagnosed with blindness due to premature birth.

The Ophtalmologist pointed out that a survey of 100 blind people carried out in the state suggested that, seven out of 10 were blind from childhood,while being hidden in that condition, till they are old enough to come out to begfor a living.

Some years back, Nigeria rose to the challenge of fighting deficiency in Vit. A and measles among children and they were successful.

Four health facilities have been designated as centres for the vision screening of children, these centres would also act as training of staffs and centres for prevention of blindness and enhancement of sight. she explained. Popoola also said that the programme will capture older children to be examined.

In her address, Omolewa Ahmed, the wife of Kwara State Governor has advocated enactmentof Law that will enforce all mothers to take their children to hospital for vision screening before enrollment in government schools.

The Governors wife who is Founder of Life Empowers Anchors Hope (LEAH) encouraged mothers to take their children to immunization centres and as well undergo vision screening as it is free of charge. Ahmed, who said the visit was embarked upon to influence immunization on children and vision screening, stated that all ministries in the state would be made to key into the programme for Kwara children to ensure preventable blindness.

Vision is important and we must ensure that out of negligence or ignorance our children are not exposed to blindness when we can take them for screening and get help, she said. She noted that some of these cases of blindness are avoidable, saying a child that is blind in young age will not havea qualitative life.

Ahmed also revealedthat recently over 200 blind citizens were empowere and N150,000 cheque was given to them each to help them in their trade. The Governors wife was shown the newly acquired vision screening equipment and how it operates.

See the original post:
Blindness: UITH examines 2500 children in kwara - BusinessDay ... - BusinessDay

Read More...

‘Bionic’ eye on the future: From ‘Star Trek’ visors to ‘Mission Impossible’ contact lenses – Fox News

February 17th, 2017 5:45 am

Could bionic eyes restore sight to the blind and give the U.S. military super sight?

Bionic implanted eyeballs, Star Trek-style visors, telescopic contact lenses ... these are just a few of the many exciting projects underway to both restore and provide enhanced sight.

Significant strides have been made in tech that will restore and transform lives - replacing white canes, service animals, braille machines and more for the visually impaired.

There has been a lot in the media about prosthetic breakthroughs for U.S. veterans, but what about vision? Last year the Blinded Veterans Association told the House and Senate Committees on Veterans Affairs that there are an estimated 131,580 legally blinded veterans in the U.S., citing data from the Depatment of Veterans Affairs.

THE 5 COOLEST MILITARY INNOVATIONS OF 2016

Technology is being increasingly harnessed to overcome blindness. So far, much of the key progress has been restricted to restoring sight for those with a specific type of visual impairment in particular retinitis pigmentosa an inherited condition that involves the loss of cells in the retina and causes a decline in vision.

BIONIC EYE IMPLANTS

One of the first and most promising bionic eyes is the Argus II made by Second Sight, which is geared toward patients with retinitis pigmentosa.

The system has two parts: a very high tech retinal implant and a camera mounted on eyeglasses or shades. The bionic eye is surgically implanted in, and on, the eye. It has an antenna, an electronics case, and an electrode array.

The camera processes what it sees and sends it to a small computer that the person wears. The data is processed and translated into instructions that are sent wirelessly to the antenna in the implant.

MARINES GET GROUNDBREAKING, UNSTOPPABLE NEW RIFLE MAGAZINE

The retinal implant has 60 electrodes in it. These electrodes provide information to the optic nerve and the optic nerve relays the data to the brain. The optic nerve understands this data as shapes, light and movement.

This vision is not yet like normal sight and it will not restore vision to 20/20. But with Argus II, folks who were once sightless can see in black and white they can read a book and see their homes and loved ones for the first time. More advances are in the pipeline for Argus II to restore color as well as resolution and brightness.

Argus II bionic eyes require functioning retina so many, including many visually impaired veterans, cant take advantage of that tech Second Sights Orion technology could be the solution.

PLUGGING INTO THE BRAIN

By skipping the optic nerve and directly plugging into the visual cortex, Orion could hold enormous potential for veterans who have visual impairment due to trauma.

'STAR TREK'-STYLE SURVEILLANCE DRONE FOR THE US MILITARY

In fact, this approach could potentially help those blinded by cancer or glaucoma.

This new device bypasses the retinal layer and implants electrodes directly onto the visual region of the brain.

Second Sight announced a major breakthrough for its Orion I project late last year. In a trial at UCLA, the very first of these devices to directly plug into the brain, a wireless visual cortical stimulator, was implanted in a human subject. The test was a success and restored vision to a 30-year old patient with no major side effects.

STAR TREK-STYLE VISOR

Ever seen Star Trek? One American company has created a sort of real-life version of character Geordi La Forges visor.

'STAR WARS'-STYLE SPEEDERS COULD CARRY US TROOPS

With the eSight 3 device, the wearer can see full-color video images without a time lag. Wherever the user looks and whatever he or she looks at, the high-speed, high-def camera captures it for them.

Advanced algorithms are used for the video feed. The video is then displayed on two screens in front of the wearers eyes. The video image is provided in a way that overcomes their vision loss.

eSight isnt a cure-all at this point. If the retina damage is too severe, then it may not work. It tends to be more helpful with macular degeneration, for example, than glaucoma. The company says the technology has about a 50 percent chance of working with all conditions.

GIVING SOLDIERS SUPER SIGHT

Advances in this field are also creating the potential to give US warfighters super vision.

HOW F-35A FIGHTER PILOTS ARE HARNESSING HIGH-TECH 'SEE-THROUGH' HELMETS

One exciting example is a new contact lens funded by DARPA, and made by cole Polytechnique Fdrale de Lausanne, that gives the wearer the ability to zoom like a telescope.

The scleral lens has thin aluminum mirrors built into it that work with special liquid crystal glasses. These glasses are connected to an electronic system.

Think Mission Impossible. If you blink your right eye, then it allows magnifying but if you wink your left then the vision is normal. If you blink normally, it doesnt trigger the magnifying mode.

In addition to the contact lens, other projects have made great headway. Even Second Sight bionic eyes can see in IR with a specific input device.

NEW TECH MAKES TANK ARMOR 'SEE-THROUGH'

Augmenting soldiers with vision-enhancing tech could provide advantages for ground troops and special operations in particular. Warfighters could switch between seeing in night vision, infrared, thermal, zoom, telescopic and more. Whether worn or implanted, it would provide enhanced capabilities that remove the weight of carrying optics and the time lost shifting optics by switching instead at the speed of thought.

Just one specific illustration of how helpful this could be is explosives. If the amazing advances in explosive detection could be miniaturized and adapted for military bionic eyes, then warfighters with enhanced vision could scan and spot these hidden IEDs before they could strike putting an end to injury and death due to IEDs.

Meet a Green Beret who was blinded in combat, but still serves, shoots with remarkable accuracy and explored Antarctica with Prince Harry at Tactical Talk this week.

Allison Barrie consults at the highest levels of defense, has travelled to more than 70 countries, is a lawyer with four postgraduate degrees and now the author of the new book "Future Weapons: Access Granted" covering invisible tanks through to thought-controlled fighter jets. You can click here for more information on FOX Firepower columnist and host Allison Barrie and you can follow her on Twitter @allison_barrie.

Read more:
'Bionic' eye on the future: From 'Star Trek' visors to 'Mission Impossible' contact lenses - Fox News

Read More...

Gene editing surgery may prevent blindness: study – India.com

February 17th, 2017 5:45 am

Seoul, Feb 17 (PTI) The gene editing tool CRISPR-Cas9 may be delivered directly into the eye to treat age-related macular degeneration (AMD) efficiently and safely, a new study has claimed.

AMD is a form of blindness, common in Caucasians, which causes distorted vision and blind spots.

Scientists at the Institute for Basic Science (IBS) in Korea used CRISPR-Cas9 in performing gene surgery in the layer of tissue that supports the retina of living mice.

The most common retinopathies causing blindness are retinopathy of prematurity in children, diabetic retinopathy and AMD in older adults.

In these diseases, abnormally high levels of the Vascular Endothelial Growth Factor (VEGF) are secreted. In AMD, VEGF causes the formation of new blood vessels in the eyes but also leads to leakages of blood and fluid into the eye, damaging an area at the center of the retina called macula.

Injections of anti-VEGF drugs are the most common treatment against AMD, but at least seven injections per year are required, because VEGF is continuously overexpressed by the cells of the diseased retinal pigment epithelium.

Instead of such invasive treatments, scientists believe that gene therapy with the third generation gene editing tool CRISPR-Cas9 could improve the situation.

The injections tackle the effects, but not the main cause of the problem. By editing the VEGF gene, we can achieve a longer-term cure, said KIM Jin-Soo, Director of the Center for Genome Engineering at IBS.

CRISPR-Cas9 can precisely cut and correct DNA at the desired site in the genome. The system works by cutting DNA at a target site, in this case, inside the VEGF gene.

Two year ago, IBS scientists proved that a pre-assembled version of CRISPR-Cas9, or Cas9 ribonucleoprotein (RNP), can be delivered to cells and stem cells to modify target genes.

The pre-assembled complex works rapidly and degrades before the body has time to build up an immune response against it.

In this study, the team successfully injected CRISPR-Cas9 into the eyes of a mice model with wet AMD and locally modified the VEGF gene.

Initially they found that the delivery of the pre-assembled CRISPR-Cas9 complex is more efficient than the delivery of the same components in a plasmid form.

Secondly, the complex disappeared after just 72 hours.

Scientists assessed the whole genome of the animals and found the CRISPR-Cas9 complex modified only the VEGF gene and did not affect other genes.

The progression of the eye disease was monitored by looking at choroidal neovascularisation (CNV), the creation of new blood vessels between the retina and the sclera a common problem of wet macular degeneration and researchers found the CNV area reduced by 58 per cent.

Moreover, a likely side effect, namely cone dysfunction, that takes only 3 days to show in these mice, did not occur a week after the treatment.

The study was published in the journal Genome Research.

This is published unedited from the PTI feed.

E Palanisamy takes oath as Tamil Nadu Chief Minister: All that happened through the day

Odisha Panchayat Election Results 2017 LIVE News Updates: BJD leads in 32, BJP in 29 and Congress in 13 of 175 Zilla Parishad seats

Mumbai University's 'first transgender' student's journey from being sexually harassed to an interior designer is inspirational!

Maharashtra Civic polls 2017: Won't back BJP if Shiv Sena withdraws support, says NCP chief Sharad Pawar

Yeh Hai Mohabbatein 16 February 2017 written update, preview: Will Ishita give Gulabo another chance?

Read more here:
Gene editing surgery may prevent blindness: study - India.com

Read More...

‘Statistical blindness’, and importance of numbers – Football365.com

February 17th, 2017 5:45 am

Date published: Friday 17th February 2017 10:45

Before wrapping up our series, I want to revisit an example from last week, for two reasons: 1) it shows the value of Expected Goals, and 2) it shows that even stats-conscious people (in this case, me) can miss the main point.

Last week we looked at the Crystal Palace Sunderland game, which finished 0-4, but 1.6 0.9 in expected goals. I noted that the xG totals were misleading, because Sunderland had scored several not-so-easy chances, then sat back and let Crystal Palace attack. What I should have added was that the xG were in one sense not misleading at all: they showed that Sunderland won big not by brilliant overall play, but by brilliant finishing. And as weve seen several times in this series, you cant rely on brilliant finishing to carry you for very long.

In other words, Sunderlands 0.9 xG tells us that as decisive as the victory was, it didnt change one of their underlying problems: the failure to create good chances. The next week against Southampton, one of the best defensive teams in the league, they wound up with a minuscule 0.2 xG and, unsurprisingly, no goals at all.

And now to wrap up, because the counter says F365 has let me spend over 10,000 words on football stats. But to say weve only scratched the surface is putting it very mildly. Football stats are a burgeoning field, and literally every day there are new ideas worth reading about. New measures are developed on a regular basis, many of which we havent even had the time to mention here. The one thing you can be sure of with football stats is that therell always be something more to learn.

Even better, many of the chief practitioners show and discuss their work publicly, and are more than willing to answer questions and share their thoughts. There are a number of excellent writers in the field, who can explain things far more complex than weve mentioned here, and write far more entertainingly doing it. There are also several good analytics podcasts, where you can hear intelligent people kick around interesting ideas, and have fun doing so.

Wheres the best place to go for football analytics? Surprisingly, its Twitter. Virtually all the experts have accounts remarking on current developments, and all provide links to the longer articles with the detailed analysis thats the meat of the subject. Here are links to some of the most prominent figures in the field, all of whom are worth reading on a daily basis:

Michael Caley, Paul Riley, Simon Gleave, Ted Knutson, James Yorke, Ben Pugsley, Mark Thompson, Mike L. Goodman, Thom Lawrence, Ben Mayhew, David Sumpter, Sander, and Dustin Ward.

Theres also a great site called Statsbomb which, although not as active as in the past, has an outstanding archive of articles. Its the site that first got me interested in analytics.

I assume anyone whos read this far has some interest in stats. But for all that they show us, we have to remember they dont have all the answers. Last year was a case in point: the stats kept saying that Leicester would fade. Around the middle of last season, having watched all the games to that point, and looked closely at the stats, I decided with self-important assurance that Spurs would win the title.

But it gets funnier. At a gathering of statisticians around the same time, somebody took an informal poll of about ten attendees on who would win the title. Going by Expected Goals and other numbers, half of them picked Arsenal.

So theres a condition which we can call statistical blindness. Stats people sometimes say Trust the numbers, not your eyes, but your eyes are there for a reason. Stats are an aid, sometimes an excellent aid, to understanding. They can tell you what to look for. But you still have to look, and you have to spot the things that stats cant reach.

To close, thanks to all the people who had kind things to say about this series. And thanks to those too who had less than kind things, because they remind you what really counts. Football is first, last, and always about love. I loved the game for almost fifty years before I even suspected there could be such a thing as football stats, and if all the numbers disappeared tomorrow, Id love it just as much. But for me, stats engage the mind in all sorts of fascinating ways. And when the mind and heart go together, theres a special kind of joy.

Peter Goldstein

Here is the original post:
'Statistical blindness', and importance of numbers - Football365.com

Read More...

Jordan youth walks to cure juvenile arthritis – SW News Media

February 17th, 2017 5:44 am

Jordans Jack Friedges is putting one foot in front of the other to help find a cure for arthritis.

Friedges will be participating in the annual Walk to Cure Juvenile Arthritis event at the Mall of America on Saturday, March 4 at 9 a.m. The event features a three-mile and one-mile course.

Friedges has also been named the Young Adult Honoree for this years event.

The cause is personal for Friedges, who was diagnosed with juvenile idiopathic arthritis (JIA) in 2014. Friedges was able to keep his arthritis under control with the help of medication, and he continues to be a three-sport athlete at Jordan High School in football, basketball and baseball.

I joined the Arthritis Foundations Walk to Cure Arthritis to help the more than 50 million Americans and 300,000 children with arthritis live better today and to keep the Arthritis Foundations promise of finding a cure for tomorrow, Friedges wrote on his donation page.

Your support provides people with arthritis life-changing resources and information to manage their disease and improves access to the critical medications they need to live full, healthy lives. The impact of your donation doesnt stop today, it also helps fund cutting-edge research to identify better treatments and a cure, Friedges added.

Friedges has set a goal of raising $5,000 for the event. As of Monday, he had raised $1,515 through his fundraising site, which can be found at http://bit.ly/2lIhosf

The Jordan Basketball Association will be hosting a fundraiser to support Friedges during the Hubmen and Jaguars basketball games on Tuesday, Feb. 21.

The girls game against Waseca will start at 6 p.m., and the boys will play Holy Family at 7:45 p.m.

Find a Cure for Juvenile Arthritis Jacks Journey bracelets will be on sale for $2, and all proceeds from the half court toss at both games will benefit the Juvenile Arthritis Foundation on Friedges behalf.

View original post here:
Jordan youth walks to cure juvenile arthritis - SW News Media

Read More...

Takeda, TiGenix stem cell therapy shows sustained effect – FierceBiotech

February 17th, 2017 5:43 am

Takeda and TiGenix have presented 52-week data on their allogeneic expanded adipose-derived stem cells in Crohns disease patients with treatment-refractory complex perianal fistulas. The data show the Cx601 stem cells continue to outperform placebo one year after administration.

TiGenix presented the 24-week data from the successful phase 3 trial back in 2015, sparking a surge in its stock price and setting it up to land a deal with Takeda. Last year it followed up with the release of a first look at 52-week results confirming the efficacy outcomes seen in the earlier data drop.

Takeda and TiGenix have now shared another overview of the 52-week data at the 12th Congress of the European Crohns and Colitis Organisation (ECCO). The abstract includes treatment-related adverse event data that were absent from TiGenixs original release, but included in subsequent presentations.

Those 52-week data confirm the positive safety profile seen in the 24-week results. The rate of treatment-emergent adverse events was lower in the Cx601 cohort than the placebo plus standard of care arm at both time points. The same is true when only serious adverse events are analyzed.

The safety results complement the previously-released efficacy data. Among the 62% of patients who completed the 52-week follow-up, the results were comparable to those generated after 24 weeks. In the Cx601 arm, 56.3% of the modified intention-to-treat (mITT) population achieved combined remission after 52 weeks, compared to 51.5% after 24 weeks. The respective figures for the placebo cohort are 38.6% and 35.6%. The mITT population included all patients to undergo at least one post-baseline efficacy evaluation.

These data highlight that the efficacy and safety of a single administration of Cx601 were maintained during one year of follow up, TiGenix CMO. Marie Paule Richard said in a statement. It is important to also note that the definition of combined remission used in the ADMIRE-CD study, which includes both clinical and radiological assessment by MRI, is more stringent than the criteria commonly used in previous large scale, randomized clinical trials evaluating perianal fistulas in Crohns disease, based only on clinical assessment.

Relapse rates in the Cx601 group were rarer, too. Three-quarters of participants who responded to Cx601 after 24 weeks made it to 52 weeks without relapsing. The number falls to 55.9% among the placebo cohort.

TiGenix is hoping the data will prove compelling enough to secure a regulatory approval in Europe later this year. In parallel, TiGenix is setting up another phase 3 trial designed to deliver data to support approval in the U.S.. TiGenix expects the trial to start later this year.

Shares in TiGenix traded up 4% shortly after the stock exchange in Brussels opened for the day.

See the original post:
Takeda, TiGenix stem cell therapy shows sustained effect - FierceBiotech

Read More...

Page 1,070«..1020..1,0691,0701,0711,072..1,0801,090..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick